KPV Oral GI-Targeted KPV
Oral capsule form of KPV designed for direct gastrointestinal mucosal contact in IBD and inflammatory gut conditions.
Book Free ConsultationCall 310.299.4444What KPV Oral actually is
Oral KPV delivers the anti-inflammatory α-MSH tripeptide directly to gastrointestinal mucosa. Kannengiesser and colleagues demonstrated efficacy in murine colitis models, supporting interest in IBD adjunct use.1
At Luxbae we prescribe oral KPV for patients with gut-targeted inflammatory goals — mild IBD adjunct (with GI coordination), post-antibiotic gut recovery, or patients with chronic gut inflammation looking to layer anti-inflammatory peptide therapy onto conventional care.
At Luxbae, KPV Oral is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.
Mechanism — Direct mucosal anti-inflammation
Oral form delivers KPV directly to gut mucosa, where it modulates NF-κB signaling and reduces pro-inflammatory cytokines.1
What the research shows
IBD adjunct. Studied in murine colitis models with positive readouts.1
Gut mucosal anti-inflammation. Direct contact with target tissue.
No injection needed. Useful for needle-averse patients.
Side effects: Generally well-tolerated. Mild GI symptoms in early dosing.
FDA note: Not FDA-approved. Compounded protocol under medical supervision.
KPV Oral FAQ
Oral vs injection?
Oral is gut-targeted; injection is systemic anti-inflammatory.
IBD use?
Adjunct, not replacement; coordinated with GI specialist.
References
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV in murine IBD. Inflamm Bowel Dis. 2008;14(3):324-331.
- Brzoska T, Luger TA, et al. Alpha-MSH-related tripeptides. Endocr Rev. 2008;29(5):581-602.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.